Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PANITUMUMAB Cause Wrong technique in product usage process? 24 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 24 reports of Wrong technique in product usage process have been filed in association with PANITUMUMAB (Vectibix). This represents 0.2% of all adverse event reports for PANITUMUMAB.

24
Reports of Wrong technique in product usage process with PANITUMUMAB
0.2%
of all PANITUMUMAB reports
0
Deaths
1
Hospitalizations

How Dangerous Is Wrong technique in product usage process From PANITUMUMAB?

Of the 24 reports, 1 (4.2%) required hospitalization.

Is Wrong technique in product usage process Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PANITUMUMAB. However, 24 reports have been filed with the FAERS database.

What Other Side Effects Does PANITUMUMAB Cause?

Rash (1,392) Diarrhoea (1,123) Death (767) Dermatitis acneiform (758) Neutropenia (757) Skin toxicity (728) Neuropathy peripheral (613) Hypomagnesaemia (611) Nausea (608) Disease progression (600)

What Other Drugs Cause Wrong technique in product usage process?

EVOLOCUMAB (21,664) ALBUTEROL (17,114) ADALIMUMAB (11,766) PEGFILGRASTIM (10,217) ETANERCEPT (9,835) ERENUMAB-AOOE (9,359) SACUBITRIL\VALSARTAN (8,022) LEUPROLIDE (5,062) FENTANYL (2,812) SEMAGLUTIDE (2,538)

Which PANITUMUMAB Alternatives Have Lower Wrong technique in product usage process Risk?

PANITUMUMAB vs PANOBINOSTAT PANITUMUMAB vs PANTOPRAZOLE PANITUMUMAB vs PANTOPRAZOLE ANHYDROUS PANITUMUMAB vs PANTOTHENIC ACID PANITUMUMAB vs PAPAVERINE

Related Pages

PANITUMUMAB Full Profile All Wrong technique in product usage process Reports All Drugs Causing Wrong technique in product usage process PANITUMUMAB Demographics